In our study, PS downregulated hepatic FGFR4 expression, and inhibition of FGFR4 signaling has been reported to improve hepatic metabolism and is a promising option for the treatment of NAFLD and HCC [44–46]. Here, FGFR4 is linked to metabolic dysfunction-associated steatotic liver disease.